Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial

NCT07248696 · clinicaltrials.gov ↗

NA

Phase

ACTIVE_NOT_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Cancinoma (NPC)

Interventions

RADIATION: response-adapted radiotherapy

Sponsor

Chongqing University Cancer Hospital